Seeking to improve graft-versus-host disease (GVHD) prophylaxis in haploidentical (HI) hematopoietic stem cell transplant (HSCT), researchers investigated a regimen of post-transplant cyclophosphamide (PTCy), abatacept (A), and a short course of tacrolimus (CAST). In a presentation of the findings at the Transplantation & Cellular Therapy 2022 Tandem Meetings, A. Samer Al-Homsi and colleagues suggested that “CAST with shortened course of T is feasible and offers promising outcomes with low rates of acute GVHD.” ...
Advertisement
A studyobserved “encouragingly” positive results in reducing severe acute graft-versus-host disease (aGVHD).
Venkata S. Thammineni, MD, and colleagues conducted a meta-analysis to assess the effect of graft CD on allo-PBSCT outcomes.
Researchers evaluated the rate of failure-free survival after belumosudil treatment for chronic graft-versus-host disease.
The investigators measured plasma vitamin E levels with high-performance liquid chromatography.
Advertisement
